<?xml version='1.0' encoding='utf-8'?>
<record xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
			<header>
				<identifier>oai:bovine-ojs-tamu.tdl.org:article/1597</identifier>
				<datestamp>2021-08-28T02:45:59Z</datestamp>
				<setSpec>bovine:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Clinical efficacy of enrofloxacin against bovine respiratory disease comparing different treatment regimens</dc:title>
	<dc:creator xml:lang="en">Hamm, M.</dc:creator>
	<dc:creator xml:lang="en">Wollen, T.</dc:creator>
	<dc:creator xml:lang="en">Highland, R.</dc:creator>
	<dc:creator xml:lang="en">Davidson, J.</dc:creator>
	<dc:creator xml:lang="en">TerHune, T.</dc:creator>
	<dc:creator xml:lang="en">Lechtenberg, K.</dc:creator>
	<dc:creator xml:lang="en">Apley, M.</dc:creator>
	<dc:creator xml:lang="en">Miles, D.</dc:creator>
	<dc:creator xml:lang="en">Wray, M.</dc:creator>
	<dc:creator xml:lang="en">Bechtol, D.</dc:creator>
	<dc:creator xml:lang="en">Waite, A.</dc:creator>
	<dc:creator xml:lang="en">Johnson, E.</dc:creator>
	<dc:creator xml:lang="en">Scott, P.</dc:creator>
	<dc:creator xml:lang="en">Copeland, D.</dc:creator>
	<dc:subject xml:lang="en">drug therapy</dc:subject>
	<dc:subject xml:lang="en">enrofloxacin</dc:subject>
	<dc:subject xml:lang="en">respiratory diseases</dc:subject>
	<dc:subject xml:lang="en">fluoroquinolone antibiotics</dc:subject>
	<dc:subject xml:lang="en">antibiotics</dc:subject>
	<dc:description xml:lang="en">Enrofloxacin is being successfully used for the treatment of respiratory disease of cattle in many countries. The established treatment regimen is a daily injection for 3 to 5 days with a dose range from 2.5 - 5.0 mg/kg. A predominant finding is that a single treatment with an higher dose of 7.5 - 12.5 mg/kg shows excellent clinical efficacy under feedlot conditions. The results of several clinical field trials conducted in the USA and Europe during the last years were used to compare the clinical efficacy of the daily and single treatment regimens. The studies were carried out under varied housing and weather conditions. The results show the equivalency of both treatment regimens. Consequently, the usage of enrofloxacin enables veterinarians to utilize their experience and medical expertise to design either a daily or a single treatment regimen according to the specific infection and management situation.</dc:description>
	<dc:publisher xml:lang="en">American Association of Bovine Practitioners</dc:publisher>
	<dc:date>1999-01-01</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://bovine-ojs-tamu.tdl.org/bovine/article/view/1597</dc:identifier>
	<dc:identifier>10.21423/bovine-vol33no1p56-59</dc:identifier>
	<dc:source xml:lang="en">The Bovine Practitioner; Vol. 33, No. 1 (1999 January); 56-59</dc:source>
	<dc:source>0524-1685</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://bovine-ojs-tamu.tdl.org/bovine/article/view/1597/1590</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 1999 American Association of Bovine Practitioners</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		
